Biogen $877 million acquisition of Nightstar Therapeutics

Overview:

• Biogen has acquired Nightstar Therapeutics for approximately $877 million.
• Biogen will acquire Nightstar via Tungsten Bidco (a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings) via a UK court-sanctioned scheme of arrangement.
• Nightstar is a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases.

Sam Duke